Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival

Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H. Moore, Garret L. Yount, Pierre-Yves Desprez and Sean D. McAllister
Jahan P. Marcu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rigel T. Christian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darryl Lau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne J. Zielinski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maxx P. Horowitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasmine Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arash Pakdel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juanita Allison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandani Limbad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan H. Moore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Garret L. Yount
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Yves Desprez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean D. McAllister
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0407 Published January 2010
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Cannabidiol (CBD) enhances the inhibitory effects of Δ9-THC on glioblastoma cell growth. To test for positive and negative interactions, a 2 × 2 factorial design using specific μmol/L concentrations of drug was used as described in Materials and Methods. Cell proliferation was measured using the MTT assay. SF126 (A) and U251 (B) cells were treated for 3 d with vehicle/no drug, Δ9-THC, cannabidiol, or a combination of Δ9-THC and cannabidiol. Concentrations of Δ9-THC and cannabidiol that produce only minimal effects on cell proliferation were also tested in 2 × 2 factorial design in SF126 (C) and U251 (D) cells. Percent control was calculated as the MTT product absorbance in the treated cells/control cells ×100. Data are the mean of at least three independent experiments; bars, ± SE. Data were analyzed using two-way ANOVA (GraphPad Prism). *, statistically significant interaction (P < 0.01). D, inset, representative light microscope image of the effects of the combination treatment on U251 cells (×40).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Δ9-THC in combination with cannabidiol does not produce a greater overall inhibition of glioma invasiveness. To test for positive and negative interactions, a 2 × 2 factorial design was used as described in Materials and Methods. The Boyden chamber invasion assay was used to determine the effects of treatment on the invasiveness of U251 cells. U251 cells were treated for 3 d with Δ9-THC (0.1 μmol/L), cannabidiol (0.1 μmol/L), or a combination of Δ9-THC (0.1 μmol/L) and cannabidiol (0.1 μmol/L). Data are presented as relative invasiveness of the cells through the Matrigel, where the respective controls are set as 100%. Data are the mean of at least three independent experiments; bars, ± SE. *, statistically significant differences from control (P < 0.05).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    The combination treatment of Δ9-THC and cannabidiol specifically inhibits ERK activity. The effects of cannabinoids on mitogen-activated protein kinases were analyzed using Western analysis. A, U251 cells were treated with vehicle or a combination of Δ9-THC (1.7 μmol/L) and cannabidiol (0.4 μmol/L) for 3 d. Proteins were then extracted and analyzed for pERK, total ERK, pJNK1/2, and pP38 MAPK. B, U251 cells were treated with Δ9-THC (1.7 μmol/L) or cannabidiol (0.4 μmol/L) alone for 3 d and analyzed for pERK and total ERK. C, U251 cells were treated with vehicle or a combination of Δ9-THC (1.7 μmol/L) and cannabidiol (0.4 μmol/L) for 1 and 2 d. D, SF126 cells were treated with vehicle or a combination of Δ9-THC (1.6 μmol/L) and cannabidiol (1.1 μmol/L) for 12 h or 1 d. Either α-tubulin or β-actin was used as a loading control (LC). Blots are representative of at least three independent experiments.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    The effects of the combination treatment are the result of CB2 receptoractivation. The number of U251 cells positive for annexin (apoptosis) staining after 3 d treatment was measured using FACS analysis. Cells were treated with A, Δ9-THC (1.7 μmol/L), cannabidiol (0.4 μmol/L), or a combination of Δ9-THC (1.7 μmol/L) and cannabidiol (0.4 μmol/L) denoted as THC/CBD; B, a combination of Δ9-THC (1.7 μmol/L) and cannabidiol (0.4 μmol/L) denoted as THC/CBD; C, 2.5 μmol/L Δ9-THC; and D, 2.0 μmol/L cannabidiol. In B, C, and D, cells were also treated in the presence of 0.5 μmol/L of the CB1 antagonist SR141716A (SR1), 0.5 μmol/L of the CB2 antagonist SR144528 (SR2), or 20 μmol/L TCP. Percent control was calculated as positive annexin staining of the treated cells minus control cells. Data are the mean of at least three independent experiments; bars, ± SE. Data were compared using one-way ANOVA with Bonferroni's multiple comparison posthoc analyses. *, statistically significant differences from control (P < 0.05); #, statistically significant differences from the combination treatment of THC/CBD (P < 0.05).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    When combined, Δ9-THC and cannabidiol produce an increase in activation of p8 and multiple caspases. The effects of cannabinoids on p8 and caspase expression were analyzed using semiquantitative reverse transcriptase-PCR and Western analysis, respectively. RNA and protein were collected from U251 cells treated for 3 d with cannabidiol (0.4 μmol/L), Δ9-THC (1.7 μmol/L), or a combination of Δ9-THC (1.7 μmol/L) and cannabidiol (0.4 μmol/L). A, reverse transcriptase-PCR was run on RNA extracted from control-treated and Δ9-THC/cannabidiol-treated samples. Expression of the β-actin gene product was used as a control for equal loading. B, data are represented as percentage p8 expression of the treated cells/control cells ×100, and all values were normalized against β-actin. Blots and PCR reactions are representative of at least three independent experiments. Data were compared using one-way ANOVA with Dunnett's multiple comparison posthoc analyses. *, statistically significant differences from control (P < 0.05). C, proteins were extracted from treated cells and analyzed for cleaved caspase 3, 7, 9, and PARP expression.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Cannabinoid modulation of cell cycle

    Treatment, μmol/LMean (G0-G1)Mean (S)Mean (G2-GM)
    CBD 0.41.08* ± 0.030.90 ± 0.050.97 ± 0.28
    Δ9-THC 1.71.12* ± 0.040.78 ± 0.111.28 ± 0.37
    Δ9-THC 1.7/CBD 0.41.23*,† ± 0.020.49*,† ± 0.082.69*,† ± 0.56

    NOTE: Cell cycle was measured using PI staining and FACS analysis, and Modfit was used to determine the percentage of cells in G0-G1, S, and G2-GM phase. U251 cells were treated for 3 d with CBD (0.4 μmol/L), Δ9-THC (1.7 μmol/L), or a combination of CBD (0.4 μmol/L) and Δ9-THC (1.7 μmol/L). The percentage of cells in each compartment was standardized by dividing it by the average percentage for the vehicle. This procedure was carried out for data from each experiment on each day. Statistical analysis was done as described in the Material and Methods.

    Abbreviation: CBD, cannabidiol.

    • ↵*P < 0.05.

    • ↵†Significant interaction.

Additional Files

  • Figures
  • Tables
  • Supplementary Data, Marcu et al.,

    Files in this Data Supplement:

    • Supplementary Figure 1
    • Supplementary Figure 2
    • Supplementary Table 1, Figure Legends 1-2
PreviousNext
Back to top
Molecular Cancer Therapeutics: 9 (1)
January 2010
Volume 9, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H. Moore, Garret L. Yount, Pierre-Yves Desprez and Sean D. McAllister
Mol Cancer Ther January 1 2010 (9) (1) 180-189; DOI: 10.1158/1535-7163.MCT-09-0407

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H. Moore, Garret L. Yount, Pierre-Yves Desprez and Sean D. McAllister
Mol Cancer Ther January 1 2010 (9) (1) 180-189; DOI: 10.1158/1535-7163.MCT-09-0407
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Material and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • G1 Arrest by Ascofuranone
  • HPV-16 and Transcriptional Gene Silencing
  • E1A Nanoparticles Enhance Cervical Cancer Radiosensitivity
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement